Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Next Previous
X
Search
Trial Profile

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlunestrant (Primary)
  • Indications Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Pharmacodynamics
  • Acronyms EMBER-2; EMBER-2 WOO
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 24 Oct 2023 Results (n=75) reporting final pharmacodynamic (PD) biomarker data from the preoperative EMBER-2 WOO study, including the expanded data at the 200 mg dose level presented at the 48th European Society for Medical Oncology Congress
    • 06 Oct 2023 According to an Eli Lilly and Company media release, the company will be presented the data from this study at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.
    • 29 Mar 2023 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top